Yahoo · Sep 30, 2026
COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies (Nasdaq: CLGN), today announced financial results for the second quarter of 2026 and provided a corporate update.
CL
NASDAQ · CLGN
CollPlant Biotechnologies Ltd.
Healthcare · Biotechnology
$3.39
Down-$0.02 (-0.59%)
Updated Oct 7, 2026, 6:37 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 23.78M
- P/E ratio
- -1.96
- Dividend yield
- 0.00%
- 52-week range
- $0.26 – $9.60
- Volume
- 25.02K
- Avg. volume
- 99.32K
Price performance · CLGN
CLGN price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
CLGN closed at $3.39 after 21 trading sessions, down 5.31% for the selected period.
- Last close
- $3.39
- Period change
- -5.31%
- Period low
- $3.39
- Period high
- $4.56
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $3.39 | $3.4899 | $3.25 | $3.39 | 25.02K |
| Oct 5, 2026 | $3.49 | $3.67 | $3.4006 | $3.41 | 7.51K |
| Oct 2, 2026 | $3.62 | $3.62 | $3.30 | $3.46 | 45.5K |
| Oct 1, 2026 | $3.84 | $3.84 | $3.55 | $3.57 | 26.27K |
| Sep 30, 2026 | $3.825 | $3.83 | $3.70 | $3.78 | 10.93K |
| Sep 29, 2026 | $3.94 | $3.94 | $3.68 | $3.79 | 21.27K |
| Sep 28, 2026 | $4.26 | $4.30 | $3.7497 | $3.87 | 31.26K |
| Sep 25, 2026 | $4.10 | $4.2901 | $4.03 | $4.25 | 24.15K |
| Sep 24, 2026 | $4.01 | $4.13 | $3.62 | $4.12 | 121.88K |
| Sep 23, 2026 | $3.76 | $4.1264 | $3.71 | $4.04 | 44.28K |
| Sep 22, 2026 | $4.30 | $4.55 | $3.74 | $3.85 | 110.85K |
| Sep 21, 2026 | $4.56 | $4.60 | $4.19 | $4.30 | 69.3K |
| Sep 18, 2026 | $4.15 | $4.78 | $4.1066 | $4.56 | 159.08K |
| Sep 17, 2026 | $3.51 | $4.20 | $3.50 | $4.16 | 183.39K |
| Sep 16, 2026 | $3.37 | $3.56 | $3.36 | $3.48 | 105.66K |
| Sep 15, 2026 | $3.51 | $3.55 | $3.38 | $3.40 | 67.9K |
| Sep 14, 2026 | $3.46 | $3.60 | $3.40 | $3.49 | 97.34K |
| Sep 11, 2026 | $3.56 | $3.70 | $3.37 | $3.50 | 126.9K |
| Sep 10, 2026 | $3.39 | $3.58 | $3.37 | $3.54 | 127.42K |
| Sep 9, 2026 | $3.51 | $3.57 | $3.30 | $3.41 | 91.06K |
| Sep 8, 2026 | $3.52 | $3.69 | $3.30 | $3.58 | 205.14K |
Latest CLGN news
The latest Smart Investors Daily articles mentioning CLGN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CLGN research
Overview
Company profile and research snapshot.
Company profile
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $12.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 6, 2026 | D. Boral Capital | Hold | — |
| Nov 28, 2025 | D. Boral Capital | Buy | — |
| Oct 20, 2025 | D. Boral Capital | Buy | — |
| Sep 16, 2025 | D. Boral Capital | Buy | — |
| Aug 21, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 30, 2026
CollPlant Biotechnologies Q2 Adj. EPS $(1.69) Misses $(0.24) Estimate, Sales $108.000K Miss $1.466M Estimate
CollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(0.24) by 604.17 percent. This is a 26.52 percent increase over losses of $(2.30)
Yahoo · Sep 24, 2026
LightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC Workloads
CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced the publication of joint research conducted by its subsidiary LightSolver Ltd. ("LightSolver"), a pioneer of pure photonic computing and developer of the Laser Processing Unit (LPU), and the High-Performance Computing Center Stuttgart (HLRS), one of Europe's premier supercomputing institutions.
Benzinga · Sep 24, 2026
CollPlant Announces Publication Of Joint Research Conducted By Its Subsidiary LightSolver Showing Photonic Computing Advantage Over GPUs
Peer-reviewed study published by ACM: LightSolver's LPU architecture demonstrated significantly lower projected time-to-solution, compared to state-of-the-art algorithms running on a GPUREHOVOT, Israel, September
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
